MRI-based cerebrovascular reactivity is associated with cognitive function independent of Alzheimer disease pathology.
The FDA has accepted for Priority Review the Biologics License Application for aducanumab for the treatment of Alzheimer disease.
Evrysdi is a survival motor neuron-2 (SMN2) splicing modifier.
The Lancet Commission added 3 new risk factors for dementia that coupled with the previous 9 lifestyle risk factors might prevent or delay up to 40% of dementias worldwide.
Years of education and the ε4 risk allele at APOE influence β-amyloid pathology in asymptomatic individuals with a parental history of sporadic AD, while only years of education influence β-amyloid pathology in presymptomatic autosomal dominant AD mutation carriers.
Plasma tau phosphorylated at threonine 217 (P-tau217) shows promise as a biomarker for Alzheimer disease (AD).
Older adults with both hearing and visual impairments – dual sensory impairment – are at a significantly increased risk for dementia.
Individuals with severe periodontal disease or edentulism have an increased risk for incident dementia.
Researchers conducted a randomized clinical trial to assess whether 24 weeks of treatment with rotigotine can modify cognitive functions in patients with mild to moderate Alzheimer disease.
Faster rates of cognitive decline were seen in association with each point worse in the multisensory function score.